Research programme: AFP drug conjugates - Alpha Cancer Technologies/PolyTherics
Latest Information Update: 30 May 2014
At a glance
- Originator Alpha Cancer Technologies; PolyTherics
- Class Antibodies; Drug conjugates
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 28 May 2014 Early research in Cancer in Canada and United Kingdom (Parenteral)